【国药集团：中国生物2个新冠灭活疫苗已经率先进入三期临床试验的最后冲刺阶段】Sinopharm CNBG is the first in the world to develop a COVID-19 inactivated vaccine, as well as the first to launch international phase III clinical trials for inactivated COVID-19 vaccines. To date, two inactivated COVID-19 vaccines developed and produced by Sinopharm are undergoing phase III clinical trials in multiple countries, including the UAE, Bahrain and Peru. 财联社9月24日讯，24日在武汉举行的第十三届中国生物产业大会上，国药集团中国生物董事长杨晓明表示，中国生物的2个新冠灭活疫苗已经率先进入三期临床试验的最后冲刺阶段。国药集团CNBG率先研制新冠肺炎灭活疫苗，并率先启动新冠肺炎灭活疫苗国际三期临床试验。目前，由国药集团研发和生产的两种COVID-19灭活疫苗正在阿联酋、巴林和秘鲁等多个国家进行三期临床试验。#新冠灭活疫苗有望年底上市#